Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology focusing on sustainable health, beauty, and wellness markets, announced that CEO John Melo will present at the Oppenheimer 24th Annual Technology, Internet & Communications Conference on August 10, 2021, at 9:55 am ET. A live webcast and replay of the presentation will be available on the company’s Investor Relations website. Amyris develops sustainable ingredients used in over 20,000 products globally.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership with Naomi Watts to launch a menopause-focused wellness brand. By 2025, over 1 billion people will experience menopause, highlighting the need for effective personal care products. The new brand aims to destigmatize menopause and provide clean, science-backed solutions. Leveraging its Lab-to-Market™ technology, Amyris seeks to lead this emerging market segment. The brand launch is expected in 2022 and will complement Amyris' existing family of consumer brands, which emphasize sustainable ingredients.
Amyris, Inc. (Nasdaq: AMRS) will release its financial results for the second quarter ended June 30, 2021, on August 5, 2021. Ahead of market opening, the company will also host a conference call at 6:00 a.m. PT (9:00 a.m. ET) to discuss the results and provide a business update, featuring executives John Melo, Han Kieftenbeld, and Eduardo Alvarez. The call will be accessible via Amyris' Investor Relations website and available for 90 days post-event.
Amyris, Inc. (Nasdaq: AMRS) announced an exclusive license with Nant Africa, LLC for its RNA COVID vaccine developed with the Infectious Disease Research Institute. The agreement could yield millions in upfront and milestone payments, along with long-term royalties. It includes funding for human clinical trials and aims for vaccine production in South Africa by year-end. The RNA technology shows comparable immunity to authorized vaccines and has lower production costs. This represents Amyris' first major pharmaceutical license, enhancing its commitment to accessible healthcare.
Amyris, Inc. (Nasdaq: AMRS) has partnered with UNCF and 10,000 Degrees to establish a $180,000 scholarship fund aimed at supporting Black and African American students in STEM, business, and marketing. The initiative underscores Amyris' commitment to diversity and education. UNCF, with over $5 billion raised, has assisted more than 500,000 students, while 10,000 Degrees has provided over $80 million in scholarships. This collaboration seeks to enhance access to education and foster a diverse workforce in the biotech sector.
Amyris, a leader in synthetic biotechnology, will have CEO John Melo present at the Jefferies Virtual Consumer Conference on June 23, 2021, at 3:15 pm ET. The event will be streamed live, with a replay available on the company’s Investor Relations page. Amyris is known for its sustainable ingredients in the Clean Health and Beauty sectors and offers popular brands such as Biossance and Pipette. The company prides itself on a No Compromise® promise of clean ingredients.
Amyris, Inc. (Nasdaq: AMRS) has announced a binding term sheet for the acquisition of clean wellness company OLIKA Inc., aiming to boost its growth in the clean health and beauty sector. OLIKA, known for its sustainable hand sanitizers, aligns with Amyris's commitment to transparent and effective ingredients. Alastair Dorward, a seasoned brand leader, will join Amyris as Chief Brand Officer. This acquisition strengthens Amyris's consumer brand portfolio, including Pipette, and is positioned to enhance their market leadership in sanitizing and household cleaning products.
Amyris (Nasdaq: AMRS), a leader in synthetic biotechnology for the Clean Health and Beauty markets, will have CEO John Melo participate in a virtual fireside chat at the Morgan Stanley 6th Annual Sustainable Futures Conference on June 9, 2021, at 3:30 pm ET. A live webcast and replay will be available on their Investor Relations page. Amyris focuses on sustainable ingredients and operates brands like Biossance and Pipette, reaching over 200 million consumers.
Amyris, Inc. (Nasdaq: AMRS), a synthetic biotechnology leader, announced it has secured commitments for over 10,000 new retail doors across North America, including major retailers like Sephora and CVS. This expansion of its clean beauty brands is expected to enhance sales over the next two quarters. The company's innovative Lab-to-Market biotechnology platform positions it uniquely within the clean health and beauty market, aiming to meet increasing consumer demand for sustainable products. John Melo emphasizes the strong market demand for high-quality, sustainable consumer products.
